MacroGenics Resultados de beneficios anteriores
Pasado controles de criterios 0/6
MacroGenics ha aumentado sus beneficios a una tasa media anual de 25.5%, mientras que los beneficios de la industria de Biotechs han experimentado un crecimiento anual de 33.8%. Los ingresos han ido creciendo a una tasa media de 8.6% al año.
Información clave
25.52%
Tasa de crecimiento de los beneficios
27.45%
Tasa de crecimiento del BPA
| Crecimiento de la industria Biotechs | 17.04% |
| Tasa de crecimiento de los ingresos | 8.57% |
| Rentabilidad financiera | -331.91% |
| Margen neto | -44.79% |
| Última actualización de beneficios | 31 Mar 2026 |
Actualizaciones de resultados anteriores recientes
Recent updates
Actualización de narrativa • May 21
MGNX: Antibody Drug Conjugate Progress Will Drive Future Upside Potential
Analysts have lifted their price target on MacroGenics to $6.75 from $3.75, citing updated assumptions on revenue trends, profitability and a lower expected P/E multiple, as well as recent positive research following the Tubulis deal and ongoing antibody drug conjugate progress. Analyst Commentary Bullish Takeaways Bullish analysts point to the higher price targets as a reflection of updated assumptions on revenue trends and profitability, suggesting they see the current valuation as more aligned with their revised models.
Actualización de narrativa • Apr 26
MGNX: Antibody Drug Conjugate Pipeline And 2026 Data Will Drive Repricing
Narrative Update on MacroGenics Analysts have raised their price targets on MacroGenics by $2 to $4. They cite updated revenue assumptions and interest in the company’s antibody drug conjugate pipeline as key factors behind the change.Actualización de narrativa • Apr 12
MGNX: Antibody Drug Conjugate Pipeline And Tubulus Deal Will Drive Repricing
Analysts raised their price target for MacroGenics from $5.00 to $9.00, citing updated assumptions for potential revenue growth, slightly higher profit margins, a lower discount rate and recent positive sentiment following the Tubulus deal and the outlook for antibody-drug conjugate data. Analyst Commentary Bullish analysts are pointing to recent research updates as a sign that expectations for MacroGenics are shifting toward a more constructive view, with price targets and ratings adjusted to reflect changing assumptions around future execution and potential revenue streams.Seeking Alpha • Apr 10
MacroGenics: Oncology Opportunities In Play, But Investing Feels Like A Gamble
Summary MacroGenics (MGNX) is rated Hold, reflecting significant upside potential but high risk and a limited funding runway beyond 2027. MGNX’s pipeline includes antibody drug conjugates and lorigerlimab, with the latter’s Phase 2 clinical hold recently lifted by the FDA. Key 2026 catalysts include clinical data from MGC026, MGC028, and the LINNET study, plus an IND submission for MGC030. Despite past setbacks and a $190m cash position, MGNX’s current valuation implies little pipeline value, making study success critical for future funding. Read the full article on Seeking AlphaArtículo de análisis • Jan 06
There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues Despite A 26% Share Price Rise
MacroGenics, Inc. ( NASDAQ:MGNX ) shareholders are no doubt pleased to see that the share price has bounced 26% in the...Actualización de narrativa • Sep 25
LORIKEET And LINNET Trials Will Spur Advances Amid Liquidity Risks
The consensus analyst price target for MacroGenics increased to $3.75, primarily reflecting a higher expected future P/E multiple despite a decline in net profit margin. What's in the News Eric Risser appointed Chief Executive Officer, succeeding long-time CEO Scott Koenig; Risser has extensive company and industry experience, having led corporate development efforts that generated $1.6 billion in non-dilutive capital.Artículo de análisis • Sep 08
MacroGenics, Inc.'s (NASDAQ:MGNX) Share Price Boosted 30% But Its Business Prospects Need A Lift Too
MacroGenics, Inc. ( NASDAQ:MGNX ) shareholders would be excited to see that the share price has had a great month...Actualización de narrativa • Aug 16
LORIKEET And LINNET Trials Will Spur Advances Amid Liquidity Risks
Despite an improving net profit margin and a sharply lower future P/E multiple reflecting more attractive valuation, the consensus analyst price target for MacroGenics has been notably reduced from $4.20 to $3.40. What's in the News Eric Risser appointed CEO, succeeding longtime leader Scott Koenig; Risser brings significant operational and business development experience, including generating over $1.6 billion in non-dilutive capital for the company.Artículo de análisis • Jul 24
MacroGenics, Inc. (NASDAQ:MGNX) Surges 37% Yet Its Low P/S Is No Reason For Excitement
MacroGenics, Inc. ( NASDAQ:MGNX ) shares have had a really impressive month, gaining 37% after a shaky period...Artículo de análisis • May 21
Analyst Forecasts For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher
MacroGenics, Inc. ( NASDAQ:MGNX ) shareholders will have a reason to smile today, with the analysts making substantial...Artículo de análisis • Apr 14
MacroGenics, Inc. (NASDAQ:MGNX) Looks Inexpensive After Falling 42% But Perhaps Not Attractive Enough
Unfortunately for some shareholders, the MacroGenics, Inc. ( NASDAQ:MGNX ) share price has dived 42% in the last thirty...
Nueva narrativa • Apr 02
LORIKEET And LINNET Trials Will Spur Advances Amid Liquidity Risks
Future revenue growth potential hinges on successful trial outcomes and product approvals in ongoing and upcoming clinical studies.Artículo de análisis • Feb 28
MacroGenics, Inc. (NASDAQ:MGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%
Unfortunately for some shareholders, the MacroGenics, Inc. ( NASDAQ:MGNX ) share price has dived 26% in the last thirty...Seeking Alpha • Feb 27
MacroGenics: Stacking Up A Lot Of Headwinds... But It's Fallen Too Far
Summary MacroGenics' valuation has declined due to continued bad news in 2024, impacting market sentiment. MGNX holds $179.6M in cash and equivalents, with a sustainable cash burn rate for up to 5 years. Sale of the margetuximab franchise poises the company for further financial stability. Operating expenses are expected to rise as clinical programs advance, with management projecting a cash runway into 2026. I think this is a conservative estimate. Although a lot has changed, I think these price levels are attractive for a tentative investment based on catalysts I anticipate in 2025 and beyond. Read the full article on Seeking AlphaSeeking Alpha • Dec 05
MacroGenics: A Productive Biotech With Growing Potential - Still Not A Buy
Summary MacroGenix was previously rated as a "Hold" due to uncertain revenue streams and high annual expenses of ~$300 million. Since the initial rating, MacroGenix's stock has dropped approximately 33%, reflecting ongoing financial challenges. The company's reliance on episodic milestones and minimal product revenues makes it unattractive for new investors. Existing investors might accept the risk, but the current financial outlook remains unattractive for prospective buyers. Read the full article on Seeking AlphaArtículo de análisis • Aug 01
Party Time: Brokers Just Made Major Increases To Their MacroGenics, Inc. (NASDAQ:MGNX) Earnings Forecasts
MacroGenics, Inc. ( NASDAQ:MGNX ) shareholders will have a reason to smile today, with the analysts making substantial...Artículo de análisis • Jul 30
MacroGenics, Inc.'s (NASDAQ:MGNX) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
MacroGenics, Inc. ( NASDAQ:MGNX ) shareholders are no doubt pleased to see that the share price has bounced 29% in the...Artículo de análisis • Jul 12
We're A Little Worried About MacroGenics' (NASDAQ:MGNX) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Artículo de análisis • May 13
MacroGenics, Inc.'s (NASDAQ:MGNX) 81% Dip In Price Shows Sentiment Is Matching Revenues
MacroGenics, Inc. ( NASDAQ:MGNX ) shareholders that were waiting for something to happen have been dealt a blow with a...Seeking Alpha • May 13
MacroGenics: Strong Likelihood Bad News Has Caused Overreaction (Rating Upgrade)
Summary Macrogenics' stock valuation has dropped over 70% after its first quarter update, creating a new opportunity for investors. The spotlight is on their product vobramitamab duocarmazine, and the phase 2 TAMARACK trial. Macrogenics has between 4 and 5 quarters of cash and investments on hand. Read the full article on Seeking AlphaSeeking Alpha • Apr 05
MacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024
Summary Positive safety update released from phase 2 TAMARACK study, using vobra duo for the treatment of patients with metastatic castration-resistant prostate cancer. Updates to interim data from the phase 2 TAMARACK study expected by May 31st of 2024. Radiographic progression-free survival data from the phase 2 TAMARACK study, expected by fall of 2024. The global prostate cancer market size is estimated to reach $27.51 billion by 2032. Read the full article on Seeking AlphaArtículo de análisis • Feb 28
MacroGenics, Inc. (NASDAQ:MGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Despite an already strong run, MacroGenics, Inc. ( NASDAQ:MGNX ) shares have been powering on, with a gain of 27% in...Seeking Alpha • Feb 15
MacroGenics: Trying To Build A Better Everything
Summary MacroGenics, Inc. has a pipeline of promising drugs including Vobramitamab Duocarmazine, Lorigerlimab, Tebotelimab, MGD024, and IMGC936. The company has a strong financial position as of their latest report. MacroGenics faces both strengths and risks in their drug development and commercialization efforts. Read the full article on Seeking AlphaArtículo de análisis • Jan 09
There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues
With a price-to-sales (or "P/S") ratio of 5.4x MacroGenics, Inc. ( NASDAQ:MGNX ) may be sending very bullish signals at...Desglose de ingresos y gastos
Desglose de ingresos y gastos
Cómo gana y gasta dinero MacroGenics. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Mar 26 | 157 | -70 | 38 | -5 |
| 31 Dec 25 | 150 | -75 | 39 | 0 |
| 30 Sep 25 | 128 | -76 | 58 | 0 |
| 30 Jun 25 | 165 | -36 | 62 | 0 |
| 31 Mar 25 | 154 | -56 | 67 | 0 |
| 31 Dec 24 | 150 | -67 | 71 | 0 |
| 30 Sep 24 | 141 | -98 | 56 | 0 |
| 30 Jun 24 | 41 | -136 | 54 | -84 |
| 31 Mar 24 | 43 | -23 | 53 | 0 |
| 31 Dec 23 | 59 | -9 | 52 | 0 |
| 30 Sep 23 | 121 | 50 | 53 | 0 |
| 30 Jun 23 | 152 | 7 | 56 | 84 |
| 31 Mar 23 | 165 | -91 | 56 | 0 |
| 31 Dec 22 | 152 | -120 | 59 | 0 |
| 30 Sep 22 | 93 | -191 | 61 | 0 |
| 30 Jun 22 | 67 | -219 | 63 | 0 |
| 31 Mar 22 | 72 | -217 | 64 | 0 |
| 31 Dec 21 | 77 | -202 | 63 | 0 |
| 30 Sep 21 | 116 | -146 | 60 | 0 |
| 30 Jun 21 | 119 | -129 | 53 | 0 |
| 31 Mar 21 | 108 | -136 | 48 | 0 |
| 31 Dec 20 | 105 | -130 | 43 | 0 |
| 30 Sep 20 | 77 | -158 | 42 | 0 |
| 30 Jun 20 | 78 | -167 | 44 | 0 |
| 31 Mar 20 | 68 | -152 | 46 | 0 |
| 31 Dec 19 | 64 | -152 | 46 | 0 |
| 30 Sep 19 | 55 | -166 | 45 | 0 |
| 30 Jun 19 | 57 | -155 | 42 | 0 |
| 31 Mar 19 | 65 | -167 | 41 | 0 |
| 31 Dec 18 | 60 | -171 | 41 | 0 |
| 30 Sep 18 | 197 | -21 | 38 | 0 |
| 30 Jun 18 | 178 | -34 | 37 | 0 |
| 31 Mar 18 | 160 | -32 | 34 | 0 |
| 31 Dec 17 | 158 | -20 | 33 | 0 |
| 30 Sep 17 | 10 | -160 | 33 | 0 |
| 30 Jun 17 | 12 | -147 | 32 | 0 |
| 31 Mar 17 | 91 | -66 | 31 | 0 |
| 31 Dec 16 | 92 | -59 | 30 | 0 |
| 30 Sep 16 | 95 | -52 | 27 | 0 |
| 30 Jun 16 | 106 | -34 | 26 | 0 |
| 31 Mar 16 | 32 | -96 | 24 | 0 |
| 31 Dec 15 | 101 | -20 | 23 | 0 |
| 30 Sep 15 | 98 | -11 | 21 | 0 |
| 30 Jun 15 | 102 | 1 | 19 | 0 |
Ingresos de calidad: MGNX actualmente no es rentable.
Margen de beneficios creciente: MGNX actualmente no es rentable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: MGNX no es rentable, pero ha reducido pérdidas en los últimos 5 años a un ritmo de 25.5% por año.
Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de MGNX en el último año con su promedio de 5 años, ya que actualmente no es rentable.
Beneficios vs. Industria: MGNX no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (43%).
Rentabilidad financiera
Alta ROE: MGNX tiene una rentabilidad financiera negativa (-331.91%), ya que actualmente no es rentable.
Rentabilidad económica
Rendimiento del capital invertido
Descubre empresas con buenos resultados en el pasado
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/26 05:56 |
| Precio de las acciones al final del día | 2026/05/26 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
MacroGenics, Inc. está cubierta por 17 analistas. 5 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Etzer Darout | Barclays |
| Peter Lawson | Barclays |
| Stephen V. Byrne | BofA Global Research |